Comparative epigenomics of human and mouse mammary tumors

Genes Chromosomes and Cancer

Volumn 48, Issue 1, 2009, Pages 83-97

  Demircan, Berna ^a   Dyer, Lisa M ^a   Gerace, Mallory ^a   Lobenhofer, Edward K ^b   Robertson, Keith D ^a   Brown, Kevin D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Division of Clinical Data ^*

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEATH ASSOCIATED PROTEIN KINASE; DUAL SPECIFICITY PHOSPHATASE 2; GLUTATHIONE TRANSFERASE P1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRICHOSTATIN A; UVOMORULIN; AZACITIDINE; CELL CYCLE PROTEIN; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; GLYCOPROTEIN; HISTONE DEACETYLASE; HYDROXAMIC ACID; REPRIMO PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; COMPARATIVE GENE MAPPING; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE FREQUENCY; GENE IDENTIFICATION; GENE SILENCING; GENE STRUCTURE; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; COMPARATIVE STUDY; DNA MICROARRAY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC EPIGENESIS; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; AZACITIDINE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DATABASES, GENETIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLYCOPROTEINS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MAMMARY NEOPLASMS, ANIMAL; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 58149389525     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20620     Document Type: Article

References (46)

1. Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD. 2006. Epigenetic silencing of the tumor suppressor cystatin m occurs during breast cancer progression. Cancer Res 66:7899-7909.
2. Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L, Gulino A. 1998. The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death Differ 5:381-389.
3. Antonicek H, Persohn E, Schachner M. 1987. Biochemical and functional characterization of a novel neuron-glia adhesion molecule that is involved in neuronal migration. J Cell Biol 104:1587-1595.
4. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. 1999. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798-802.
5. Bird A. 1992. The essentials of DNA methylation. Cell 70:5-8.
6. Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21.
7. Bishop DT. 1999. BRCA1 and BRCA2 and breast cancer incidence: A review. Ann Oncol 10 (Suppl 6):113-119.
8. Chalmers IJ, Aubele M, Hartmann E, Braungart E, Werner M, Hofler H, Atkinson MJ. 2001. Mapping the chromosome 16 cad-herin gene cluster to a minimal deleted region in ductal breast cancer. Cancer Genet Cytogenet 126:39-44.
9. Chen F. 2004. Endogenous inhibitors of nuclear factor-kB, an opportunity for cancer control. Cancer Res 64:8135-8138.
10. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K. 1996. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 271:6497-6501.
11. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. 2003. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150.
12. Dobretsov M, Stimers JR. 2005. Neuronal function and α3 isoform of the Na/K-ATPase. Front Biosci 10:2373-2396.
13. Dobrovic A, Simpfendorfer D. 1997. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347-3350.
14. Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R. 1997. Loss of heterozygosity on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer 19:185-191.
15. Esteller M. 2007. Cancer epigenomics: DNA methylomes and his-tone-modification maps. Nat Rev Genet 8:286-298.
16. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabriel-son E, Schutte M, Baylin SB, Herman JG. 2000. Promoter hy-permethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569.
17. Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229.
18. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. 2000. High frequency of hypermethylation at the 14-3-3 ∑ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97:6049-6054.
19. Gardiner-Garden M, Frommer M. 1987. CpG islands in vertebrate genomes. J Mol Biol 196:261-282.
20. Gloor S, Antonicek H, Sweadner KJ, Pagliusi S, Frank R, Moos M, Schachner M. 1990. The adhesion molecule on glia (AMOG) is a homologue of the ß subunit of the Na,K-ATPase. J Cell Biol 110:165-174.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
22. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, Tlsty TD. 2003. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63:1596-1601.
23. Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD, Weiss WA, Costello JF. 2005. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res 65:3617-3623.
24. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nat Genet 21:163-167.
25. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
26. Katoh M. 2004. Human FOX gene family (review). Int J Oncol 25:1495-1500.
27. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, Stain S, Chapman WC, Washington MK, Willis J, Markowitz SD, Grady WM. 2006. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45:781-789.
28. Lin L, Spoor MS, Gerth AJ, Brody SL, Peng SL. 2004. Modulation of Th1 activation and inflammation by the NF-kB repressor Foxj1. Science 303:1017-1020.
29. Lu T, Stark GR. 2004. Cytokine overexpression and constitutive NFkB in cancer. Cell Cycle 3:1114-1117.
30. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK. 2002. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 277:41128-41139.
31. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR. 2000. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res 60:4346-4348.
32. Robertson KD. 2005. DNA methylation and human disease. Nat Rev Genet 6:597-610.
33. Senner V, Schmidtpeter S, Braune S, Puttmann S, Thanos S, Bartsch U, Schachner M, Paulus W. 2003. AMOG/ß2 and glioma invasion: Does loss of AMOG make tumour cells run amok? Neuropathol Appl Neurobiol 29:370-377.
34. Stoffel W, Jenke B, Holz B, Binczek E, Gunter RH, Knifka J, Koebke J, Niehoff A. 2007. Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am J Pathol 171:153-161.
35. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408.
36. Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M, Stastny V, Augustus M, Wu CW, Wistuba II, Meltzer SJ, Gazdar AF. 2005. Aberrant methylation of reprimo in human malignancies. Int J Cancer 115:503-510.
37. Tost J, Dunker J, Gut IG. 2003. Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques 35:152-156.
38. van den Boom J, Wolter M, Blaschke B, Knobbe CB, Reifen-berger G. 2006. Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription- polymerase chain reaction. Int J Cancer 119:2330-2338.
39. Vo QN, Kim WJ, Cvitanovic L, Boudreau DA, Ginzinger DG, Brown KD. 2004. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 23:9432-9437.
40. Weinberg RA. 1996. How cancer arises? Sci Am 275:62-70.
41. Wolffe AP. 2001. Chromatin remodeling: Why it is important in cancer. Oncogene 20:2988-2990.
42. Wu P, Qi B, Zhu H, Zheng Y, Li F, Chen J. 2007. Suppression of staurosporine-mediated apoptosis in Hs578T breast cells through inhibition of neutral-sphingomyelinase by caveolin-1. Cancer Lett 256:64-72.
43. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighau-sen L, Wynshaw-Boris A, Deng CX. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43.
44. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422:527-531.
45. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C. 2005a. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37:265-274.
46. Yu YP, Paranjpe S, Nelson J, Finkelstein S, Ren B, Kokkinakis D, Michalopoulos G, Luo JH. 2005b. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 26:471-479.